Last reviewed · How we verify

EZE/simvastatin

Azienda Ospedaliero Universitaria di Sassari · FDA-approved active Small molecule

EZE/simvastatin combines ezetimibe (which blocks cholesterol absorption in the intestine) with simvastatin (which inhibits HMG-CoA reductase to reduce cholesterol synthesis) for dual lipid-lowering action.

EZE/simvastatin combines ezetimibe (which blocks cholesterol absorption in the intestine) with simvastatin (which inhibits HMG-CoA reductase to reduce cholesterol synthesis) for dual lipid-lowering action. Used for Hypercholesterolemia and mixed dyslipidemia.

At a glance

Generic nameEZE/simvastatin
SponsorAzienda Ospedaliero Universitaria di Sassari
Drug classCombination lipid-lowering agent (ezetimibe + statin)
TargetNPC1L1 transporter (ezetimibe); HMG-CoA reductase (simvastatin)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Ezetimibe selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the intestinal brush border, reducing dietary and biliary cholesterol absorption. Simvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. Together, these complementary mechanisms provide additive LDL-cholesterol reduction beyond either agent alone.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: